Ocugen-Bharat Biotech Partnered COVID-19 Booster Covaxin Neutralizes Omicron, Delta Variants

Ocugen Inc OCGN and its partner, Bharat Biotech, announced results from a COVID-19 vaccine booster study conducted at Emory University.

• The data demonstrated sera from subjects who received a booster dose of candidate vaccine Covaxin six months after getting a primary two-dose series of Covaxin neutralized the SARS-CoV-2 Omicron and Delta variants. 
• Earlier studies demonstrated the neutralizing potential of the vaccine against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta, and Kappa.
• Related: Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose.
• The study will be published on the pre-print server, medRXiv, in the coming days.
• The neutralization activity of COVAXIN-boosted sera was comparable to that observed in mRNA vaccine-boosted sera against the Omicron variant. 
• More than 90% of all individuals boosted with Covaxin showed neutralizing antibodies. 
• Price Action: OCGN shares are up 2.76% at $4.28 during the market session on the last check Wednesday.